Our Experts Comment the Times Series

See All the Comments

Bayer Update

07 July 2020 by jbchevrel

Bayer AG is in all Mains. Bayer segments are Pharmaceuticals (prescription products and specialty therapeutics), Consumer Health (non-prescription otc products in dermatology, dietary, analgesic, etc), Crop Science (crop protection solutions and seeds – incl. Monsanto) and Animal Health (veterinary products). After Leverkusen’s final defeat 2/4 vs Bayern Munich last Saturday, here is another setback for Bayer. Today Bayer AG 5y CDS widened +5 to 62.5. That marks a small under-performance locally as both Main s33 and its fair value are wider by just +1. Pre-COVID, Bayer 5y CDS was 45, peaked 130. So Bayer retraced 80% of COVID widening. Today Bayer under-performed after US District Judge Vince Chhabria expressed skepticism about Bayer’s proposed treatment of future claims. That comes after Bayer had announced a $11B settlement. Mr Chhabria described a plan to create a class action for future litigants as problematic in a court filing Monday and said he was “tentatively inclined” to reject it. He set a July 24 hearing date. Bayer has already agreed to resolve about 95k out of the 125k existing lawsuits. In parallel with CDS +5 widening, market value came down -5%. It had dropped -43% on COVID, reverted to -6% (2/17 start date, c2c) now -18%. The key question is surely about quantifying the future set of claimants (30k unresolved cases at the moment - this number has upside potential). Meanwhile, Bayer is set to report Q2 in a bit less than a month, on Aug 4.